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Bivalirudin in Acute Coronary Syndromes
To the Editor: Valgimigli et al. (Sept. 10 issue)1 
report that prolongation of the bivalirudin infu-
sion after the completion of coronary interven-
tion did not significantly reduce the risk of early 
stent thrombosis with bivalirudin as compared 
with the periprocedural use of unfractionated 
heparin. The rapid and opposing endothelial 
 effects of bivalirudin and heparin have been de-
scribed previously.2 Bivalirudin enhances the vas-
cular sequestration of neutrophil-derived myelo-
peroxidase, which has the effect of accelerating 
the consumption of nitric oxide and depressing 
its bioavailability.2 In contrast, heparin liberates 
vessel-bound myeloperoxidase and improves en-
dothelial function.2 The bivalirudin–myeloper-
oxidase–nitric oxide interaction may predispose 
patients to early stent thrombosis during acute 
myocardial infarction. First, neutrophil activa-
tion is an early event in acute myocardial infarc-
tion.3 Second, interactions between activated 
platelets and neutrophils stimulate the forma-
tion of so-called neutrophil extracellular traps 
(chromatin filaments released from neutrophils) 
bearing active tissue factor in the infarct-related 
artery,4 which further induces thrombin genera-
tion and platelet activation. Third, blockade of 
the platelet P2Y12-receptor boosts the capacity of 
nitric oxide to inhibit thrombin-stimulated plate-
let activation and aggregation by a factor of 1000 
to 100,000.5 Thus, the bivalirudin-mediated vascu-
lar immobilization of neutrophil-derived myelo-
peroxidase might contribute to early stent throm-
bosis during acute myocardial infarction as a 
result of the inactivation of endogenous nitric 
oxide that occurs before there is fully effective 
platelet inhibition, just after loading doses of oral 
P2Y12 antagonists have been administered.
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To the Editor: In a post hoc analysis, the Euro-
pean Ambulance Acute Coronary Syndrome An-
giography (EUROMAX) investigators found that 
the risk of acute stent thrombosis can be elimi-
nated by means of the continued use of a full 
dose of bivalirudin (1.75 mg per kilogram of 
body weight per hour) after percutaneous coro-
nary intervention (PCI), but not a reduced dose 
(0.25 mg per kilogram of body weight per hour).1 
The Bivalirudin in Acute Myocardial Infarction 
vs. Glycoprotein IIb/IIIa and Heparin: A Random-
ized Controlled Trial (BRIGHT) investigators 
therefore mandated in their protocol that only a 
full dose of bivalirudin should be continued after 
PCI, which eliminated the increased risk of acute 
stent thrombosis as compared with heparin in 
that trial.2 Unfortunately, the Minimizing Ad-
verse Hemorrhagic Events by Transradial Access 
Site and Systemic Implementation of Angiox 
(MATRIX) investigators let individual practitio-
ners select the doses of bivalirudin, which led the 
majority of practitioners to use reduced doses. 
MATRIX only proved that a reduced dose of bi-
valirudin does not prevent acute stent thrombo-
sis; it did not disprove the beneficial effect of a 
full dose of bivalirudin, as was observed in the 
BRIGHT trial. Even the MATRIX study suggested 
a dose–response phenomenon: as shown by Val-
gimigli et al. in Table S5 in the Supplementary 
Appendix of their article (available at NEJM.org), 
the incidence of definite stent thrombosis in the 
group receiving the full dose of bivalirudin was 
lower than it was in the reduced-dose group 
(0.2% vs. 2.1%). If the MATRIX investigators had 
used a full dose of bivalirudin for all their pa-
tients, their results might have been different.
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The author and a colleague reply: Surdacki 
et al. speculate that the null effect of the post-PCI 
infusion of bivalirudin on ischemic events ob-
served in the MATRIX trial is due to an inter-
action between bivalirudin and myeloperoxidase. 
In particular, the authors mention the role of 
bivalirudin in the sequestration of neutrophil-
derived myeloperoxidase,1 which reduces the 
availability of nitric oxide. It remains unclear 
whether this observation pertains to patients 
with acute coronary syndromes, since these data 
were generated primarily in vitro and were only 
partially corroborated in 30 patients undergoing 
elective PCI. This biochemical finding was ob-
served only in patients receiving the full dose of 
bivalirudin (0.75 mg per kilogram followed by an 
infusion of 1.75 mg per kilogram per hour), and 
it is explained by the stoichiometric sequestra-
tion of myeloperoxidase by bivalirudin, which is 
presumably a dose-related effect.1 Hence, a lower-
dose regimen of bivalirudin, such as the 0.25 mg 
per kilogram per hour used in the MATRIX trial, 
should minimize the risk of the stoichiometric 
sequestration of myeloperoxidase.
However, like others,2,3 we have observed an 
excess of ischemic events in patients receiving 
the low post-PCI dose of bivalirudin or no post-
PCI bivalirudin, but not during PCI or in those 
receiving the full-dose PCI–bivalirudin regimen 
after intervention. Hence, the myeloperoxidase 
interaction is unlikely to explain our results. The 
absence of bivalirudin (or a less-than-ideal con-
centration) after PCI is more likely to explain our 
clinical findings than the postulated off-target 
effect of bivalirudin. The absence of any signal 
suggesting higher ischemic hazards during or at 
the end of intervention (i.e., intraprocedural 
thrombotic events, final Thrombolysis in Myo-
cardial Infarction [TIMI] flow grade <3, or peri-
procedural myocardial infarction) among patients 
receiving the full-dose bivalirudin regimen argues 
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against the possibility that the bivalirudin-induced 
sequestration of myeloperoxidase carries clinical 
implications.
We agree with Shah that the MATRIX results 
do not disprove the potential effectiveness of 
bivalirudin in reducing the risk of postinter-
vention thrombotic events when administered 
after PCI in the full-dose regimen. The BRIGHT 
study findings were reported only after recruit-
ment for the MATRIX trial had been complet-
ed, whereas the EUROMAX trial,4 which was 
reported in 2013, led to a strong preference for 
the full-dose bivalirudin regimen for patients 
enrolled in the post-PCI–infusion group of the 
MATRIX trial after that date. Ischemic risks, 
including stent thrombosis, were low among 
patients receiving the full-dose, post-PCI regi-
men in our study. Whether this is a real find-
ing or the result of selection bias remains to be 
ascertained.
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Chemohormonal Therapy in Hormone-Sensitive Prostate Cancer
To the Editor: Sweeney et al. (Aug. 20 issue)1 
report a marked survival advantage with con-
comitant docetaxel and androgen-deprivation 
therapy (ADT), as compared with ADT alone, in 
patients with hormone-sensitive metastatic pros-
tate cancer. However, it would be interesting to 
compare the experimental group with the sub-
group of the control group that received subse-
quent docetaxel after the development of castra-
tion resistance to clarify the effect of timing on 
patient outcomes. In addition, the survival bene-
fit was more pronounced in high-risk patients, 
with an extraordinary hazard ratio of 0.61. This 
underlines the need for more accurate models 
integrating data on disease volume with patient 
age and coexisting conditions to avoid selection 
biases based only on the number and sites of 
metastases.
The development of molecular biomarkers to 
predict the biologic aggressiveness of prostate 
cancer or the sensitivity of tumors to a specific 
therapy is still in the early stages. This is par-
tially due to tumor heterogeneity, with the co-
existence of androgen-sensitive and resistant 
clones across different metastases.2 In this sce-
nario, is it conceivable to evaluate the expression 
of the splice variant ARv567, a biomarker of 
taxanes sensitivity,3 to personalize the approach 
to patients who have not previously received hor-
mone therapy?
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